TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Immutep ( (IMMP) ) has provided an announcement.
Immutep Limited announced positive results from the EFTISARC-NEO Phase II trial, presented at the CTOS 2025 Annual Meeting. The trial, which involved a novel combination of eftilagimod alfa (efti) with radiotherapy and KEYTRUDA® for resectable soft tissue sarcoma, showed significant tumor hyalinization/fibrosis and strong immune activation. These findings suggest potential for improved patient outcomes and survival rates, highlighting efti’s role in enhancing immune response against cancer. The promising data supports further investigation into efti’s use in earlier-stage cancers, potentially expanding its application to patients with lower tumor burdens.
The most recent analyst rating on (IMMP) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Immutep stock, see the IMMP Stock Forecast page.
Spark’s Take on IMMP Stock
According to Spark, TipRanks’ AI Analyst, IMMP is a Neutral.
Immutep’s overall stock score reflects significant financial challenges, with persistent losses and negative cash flows being the most impactful factors. The technical analysis indicates a bearish trend, and the valuation highlights the risks associated with ongoing unprofitability. Improvements in financial performance and operational efficiency are necessary for a more favorable outlook.
To see Spark’s full report on IMMP stock, click here.
More about Immutep
Immutep is a late-stage biotechnology company focused on developing novel immunotherapies for cancer and autoimmune diseases. The company is a leader in the field of Lymphocyte Activation Gene-3 (LAG-3) related therapeutics, aiming to stimulate or suppress the immune response. Immutep’s product portfolio includes treatments for various cancers, leveraging its expertise to provide innovative options for patients and maximize shareholder value.
Average Trading Volume: 130,590
Technical Sentiment Signal: Sell
Current Market Cap: $260M
Learn more about IMMP stock on TipRanks’ Stock Analysis page.